CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 104 enrolled
Drug / intervention
Citicoline +1 moredrug
Likely dose
Citicoline 1gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00950352
NCT00950352Phase 3Completed
CompareCT.gov

Citicoline Treatment of Methamphetamine Dependence

Perry Renshaw·interventional·Posted Jul 31, 2009·Updated Feb 11, 2015

In Brief

A Phase 3 clinical trial evaluating Citicoline and Placebo for Methamphetamine Dependence. Completed, enrolled 104 participants across 1 site.

Detailed Summary

The purpose of the study is to determine if citicoline (a nutritional supplement) is effective in helping people reduce their dependence on methamphetamine. The investigators will use neuroimaging to look at the structure and chemical make up of the brain at the start of the study and after 8-9 weeks of treatment of citicoline or placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMethamphetamine Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 31, 2009
Enrollment StartJan 1, 2010
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 16.9 years ago

Interventions

Citicolinedrug

Subjects will be given 1g citicoline twice daily for a total of 8-9 weeks.

Placebodrug

Subjects will be given 1 capsule of placebo twice daily for 8-9 weeks. They will be taking the same quantity as the citicoline group.